{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T21:11:42Z","timestamp":1764364302113,"version":"3.41.0"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2017,8,12]],"date-time":"2017-08-12T00:00:00Z","timestamp":1502496000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1007\/s40259-017-0240-7","type":"journal-article","created":{"date-parts":[[2017,8,12]],"date-time":"2017-08-12T03:30:24Z","timestamp":1502508624000},"page":"461-464","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["SB2: An Infliximab Biosimilar"],"prefix":"10.1007","volume":"31","author":[{"given":"Yvette N.","family":"Lamb","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lesley J.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma D.","family":"Deeks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,8,12]]},"reference":[{"key":"240_CR1","unstructured":"European Medicines Agency. Flixabi: EU prescribing information. 2016. http:\/\/www.ema.europa.eu\/ . Accessed 27 July 2017."},{"key":"240_CR2","unstructured":"Samsung Bioepis. Samsung Bioepis obtains first drug approval in the United States, as the U.S. Food and Drug Administration approves RENFLEXIS\u2122 (Infliximab-abda) across all eligible indications [media release]. 2017. http:\/\/www.samsungbioepis.com . Accessed 27 July 2017."},{"key":"240_CR3","unstructured":"European Medicines Agency. Flixabi CHMP assessment report. 2016. http:\/\/www.ema.europa.eu\/ . Accessed 27 July 2017."},{"issue":"2","key":"240_CR4","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1080\/19420862.2016.1264550","volume":"9","author":"J Hong","year":"2017","unstructured":"Hong J, Lee Y, Lee C, et al. Physicochemical and biological characterization of SB2, a biosimilar of Remicade\u00ae (infliximab). mAbs. 2017;9(2):365\u201383.","journal-title":"mAbs"},{"key":"240_CR5","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1136\/annrheumdis-2015-207764","volume":"76","author":"J-Y Choe","year":"2017","unstructured":"Choe J-Y, Prodanovic N, Niebrzydowski J, et al. A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis. 2017;76:58\u201364.","journal-title":"Ann Rheum Dis"},{"key":"240_CR6","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex254","author":"JS Smolen","year":"2017","unstructured":"Smolen JS, Choe J-Y, Prodanovic N, et al. Comparing biosimilar SB2 with reference infliximab after 54\u00a0weeks of a double-blind trial: clinical, structural and safety results. Rheumatology. 2017. doi: 10.1093\/rheumatology\/kex254 .","journal-title":"Rheumatology"},{"issue":"6","key":"240_CR7","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s40259-015-0150-5","volume":"29","author":"D Shin","year":"2015","unstructured":"Shin D, Kim Y, Kim YS, et al. A randomized, phase I pharmacokinetic study comparing SB2 and infliximab reference product (Remicade\u00ae) in healthy subjects. BioDrugs. 2015;29(6):381\u20138.","journal-title":"BioDrugs"},{"issue":"Suppl 2","key":"240_CR8","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1136\/annrheumdis-2016-eular.3122","volume":"75","author":"JS Smolen","year":"2016","unstructured":"Smolen JS, Choe J-Y, Prodanovic N, et al. Comparable safety and immunogenicity and sustained efficacy after transition to SB2 (an infliximab biosimilar) vs ongoing infliximab reference product in patients with rheumatoid arthritis: results of phase III transition study [abstract no. FRI0162]. Ann Rheum Dis. 2016;75(Suppl 2):488.","journal-title":"Ann Rheum Dis"}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40259-017-0240-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-017-0240-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-017-0240-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T22:25:53Z","timestamp":1750803953000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40259-017-0240-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,12]]},"references-count":8,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["240"],"URL":"https:\/\/doi.org\/10.1007\/s40259-017-0240-7","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"type":"print","value":"1173-8804"},{"type":"electronic","value":"1179-190X"}],"subject":[],"published":{"date-parts":[[2017,8,12]]}}}